GU5 Stock Overview
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People’s Republic of China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.34 |
| 52 Week High | HK$3.14 |
| 52 Week Low | HK$2.10 |
| Beta | 0.65 |
| 1 Month Change | 7.34% |
| 3 Month Change | 2.63% |
| 1 Year Change | -18.18% |
| 3 Year Change | 12.50% |
| 5 Year Change | -47.33% |
| Change since IPO | 94.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| GU5 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 2.6% | 5.4% | 1.7% |
| 1Y | -18.2% | 0.6% | 2.3% |
Return vs Industry: GU5 underperformed the German Healthcare industry which returned 1.9% over the past year.
Return vs Market: GU5 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| GU5 volatility | |
|---|---|
| GU5 Average Weekly Movement | 4.0% |
| Healthcare Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GU5 has not had significant price volatility in the past 3 months.
Volatility Over Time: GU5's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 28,048 | Hong Li | www.gybys.com.cn |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People’s Republic of China and internationally. The company operates through four segments: Great Southern Medicine, Great Commerce, Great Health, and Great Medical Care. It is also involved in the wholesale, retail, sale, import, and export of Western and Chinese medicines, and medical devices; and research and development, production, and sale of beverages, food, healthcare products, and other products; and production and sale of pre-packaged food, dairy products, etc., as well as offers herbal tea, tablets, capsules, lozenges, Guiling jellies, etc. In addition, the company invests in health industry, such as medical services, health management, health care, elderly care, etc.; and provides business and advertising agency services.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Fundamentals Summary
| GU5 fundamental statistics | |
|---|---|
| Market cap | €6.22b |
| Earnings (TTM) | €522.98m |
| Revenue (TTM) | €9.74b |
7.6x
P/E Ratio0.4x
P/S RatioIs GU5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GU5 income statement (TTM) | |
|---|---|
| Revenue | CN¥75.52b |
| Cost of Revenue | CN¥61.37b |
| Gross Profit | CN¥14.14b |
| Other Expenses | CN¥10.09b |
| Earnings | CN¥4.06b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 2.49 |
| Gross Margin | 18.73% |
| Net Profit Margin | 5.37% |
| Debt/Equity Ratio | 30.4% |
How did GU5 perform over the long term?
See historical performance and comparison